Mind Medicine股价因拟议证券发行而下跌

• Mind Medicine (NASDAQ:MNMD) shares fell over 5% Friday morning after the biopharmaceutical company proposed a public offering of common shares and pre-funded warrants to purchase common shares.
• Net proceeds from this offering will be used to fund the research and development of its product candidates and working capital and general corporate purposes.
• Leerink Partners and Evercore ISI are acting as the joint bookrunning managers for the offering. RBC Capital Markets and Oppenheimer & Co. are acting as lead managers.

More on Mind Medicine

• MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy
• MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors
• Psychedelics Closer To Commercialization; Compass Far And Away The Leader
• RBC recommends buying MindMed amid psychedelic stocks sell-off (update)
• Biggest stock movers today: WKME, CRWD, HPE, and more